Skip to main content
Erschienen in: International Journal of Hematology 2/2017

11.10.2016 | Original Article

A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity

verfasst von: Tomoko Matsumoto, Keiji Nogami, Midori Shima

Erschienen in: International Journal of Hematology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Patients with mild/moderate hemophilia (H)A, acquired HA (AHA) and lupus anticoagulants (LA), have prolonged aPTTs with low levels of factor (F)VIII activity, but the differentiation of these disorders is complex and time consuming. We established an approach to quickly differentiate these disorders using comprehensive coagulation tests. Patients’ plasmas with mild/moderate HA, AHA, LA without anti-phospholipid syndrome [LA-APS(−)], and LA with APS [LA-APS(+)] were examined using clot waveform analysis (CWA) and thrombin generation test (TGT). Activated protein C (APC) sensitivity was assessed by TGT. CWA revealed similarly prolonged clot times in all groups [NP/mild/moderate HA/AHA/LA-APS(−)/LA-APS(+); 33 ± 1/82 ± 12/116 ± 44/90 ± 29/96 ± 15 s] but significantly different decreased maximal coagulation velocity (3.1 ± 0.1/1.3 ± 0.3/0.9 ± 0.5/1.6 ± 0.3/2.2 ± 0.5). In TGT, AHA group demonstrated severely reduced peak-thrombin levels (362 ± 23/170 ± 27/49 ± 21/158 ± 75/158 ± 99 nM), whilst both LA groups markedly prolonged lag times (4.5 ± 0.3/5.0 ± 0.4/4.7 ± 0.8/12.5 ± 7.7/28.8 ± 11.8 min), suggesting that AHA could be readily identified, but the different LA sub-types failed to be classified. An APC sensitivity demonstrated that ‘normalized’ APC-induced levels of peak thrombin in LA-APS(+) were significantly lower relative to LA-APS(−) (normalized %inhibition; 5 ± 7/42 ± 39 %). Our studies confirmed that %inhibition by APC was significantly decreased in NP preincubated with purified IgGs from LA-APS(+) compared to LA-APS(−), facilitating differentiation between LA groups. A combined approach using CWA and TGT could be a useful means of differentiating coagulation disorders with prolonged aPTT.
Literatur
1.
Zurück zum Zitat White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.PubMed White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.PubMed
2.
Zurück zum Zitat Kessler CM, Knöbl P. Acquired haemophilia: an overview for clinical practice. Eur J Haematol. 2015;95(Suppl 81):36–44.CrossRefPubMed Kessler CM, Knöbl P. Acquired haemophilia: an overview for clinical practice. Eur J Haematol. 2015;95(Suppl 81):36–44.CrossRefPubMed
3.
Zurück zum Zitat Robertson B, Greaves M. Antiphospholipid syndrome: an evolving story. Blood Rev. 2006;20:201–12.CrossRefPubMed Robertson B, Greaves M. Antiphospholipid syndrome: an evolving story. Blood Rev. 2006;20:201–12.CrossRefPubMed
4.
Zurück zum Zitat Baca V, Montiel G, Meillón L, Pizzuto J, Catalan T, Juan-Shum L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol. 2002;71:200–7.CrossRefPubMed Baca V, Montiel G, Meillón L, Pizzuto J, Catalan T, Juan-Shum L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol. 2002;71:200–7.CrossRefPubMed
5.
Zurück zum Zitat Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie. 2010;30:207–11.PubMed Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie. 2010;30:207–11.PubMed
6.
Zurück zum Zitat Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost. 2013;109:1007–15.CrossRefPubMed Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost. 2013;109:1007–15.CrossRefPubMed
7.
Zurück zum Zitat Tiede A, Werwitzke S, Scharf RE. Laboratory Diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40:803–11.CrossRefPubMed Tiede A, Werwitzke S, Scharf RE. Laboratory Diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40:803–11.CrossRefPubMed
8.
Zurück zum Zitat Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.PubMed Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.PubMed
9.
Zurück zum Zitat Shima M, Matsumoto T, Fukuda Y, Kubota Y, Tanaka I, Nishiya K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost. 2002;87:436–41.PubMed Shima M, Matsumoto T, Fukuda Y, Kubota Y, Tanaka I, Nishiya K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost. 2002;87:436–41.PubMed
10.
Zurück zum Zitat Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006;4:377–84.CrossRefPubMed Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006;4:377–84.CrossRefPubMed
11.
Zurück zum Zitat Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost. 2013;11:1417–20.CrossRefPubMed Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost. 2013;11:1417–20.CrossRefPubMed
12.
Zurück zum Zitat Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin generation assays. Semin Thromb Hemost. 2008;34:670–82.CrossRefPubMed Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin generation assays. Semin Thromb Hemost. 2008;34:670–82.CrossRefPubMed
13.
Zurück zum Zitat Matsumoto T, Nogami K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost. 2012;107:288–301.CrossRefPubMed Matsumoto T, Nogami K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost. 2012;107:288–301.CrossRefPubMed
14.
Zurück zum Zitat Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol. 2004;26:215–23.CrossRefPubMed Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol. 2004;26:215–23.CrossRefPubMed
15.
Zurück zum Zitat Kasper CK, Aledort LM, Aronson D, Counts R, Edson JR, van Eys J, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869. Kasper CK, Aledort LM, Aronson D, Counts R, Edson JR, van Eys J, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869.
16.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed
17.
Zurück zum Zitat Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009;90:576–82.CrossRefPubMed Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009;90:576–82.CrossRefPubMed
18.
Zurück zum Zitat Liestøl S, Sandset PM, Mowinckel MC, Wisløff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204–10.CrossRefPubMed Liestøl S, Sandset PM, Mowinckel MC, Wisløff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204–10.CrossRefPubMed
19.
Zurück zum Zitat Solano C, Zerafa P, Bird R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. Int J Lab Hematol. 2011;33:67–78.CrossRefPubMed Solano C, Zerafa P, Bird R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. Int J Lab Hematol. 2011;33:67–78.CrossRefPubMed
20.
Zurück zum Zitat Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010;28(115):870–8.CrossRef Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010;28(115):870–8.CrossRef
21.
Zurück zum Zitat Nojima J, Iwatani Y, Ichihara K, Tsuneoka H, Ishikawa T, Yanagihara M, et al. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Thromb Res. 2009;124:127–31.CrossRefPubMed Nojima J, Iwatani Y, Ichihara K, Tsuneoka H, Ishikawa T, Yanagihara M, et al. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Thromb Res. 2009;124:127–31.CrossRefPubMed
22.
Zurück zum Zitat Ames PR, Graf M, Archer J, Scarpato N, Iannaccone L. Prolonged activated partial thromboplastin time: difficulties in discriminating coexistent factor VIII inhibitor and lupus anticoagulant. Clin Appl Thromb Hemost. 2015;21:149–54.CrossRefPubMed Ames PR, Graf M, Archer J, Scarpato N, Iannaccone L. Prolonged activated partial thromboplastin time: difficulties in discriminating coexistent factor VIII inhibitor and lupus anticoagulant. Clin Appl Thromb Hemost. 2015;21:149–54.CrossRefPubMed
Metadaten
Titel
A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity
verfasst von
Tomoko Matsumoto
Keiji Nogami
Midori Shima
Publikationsdatum
11.10.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2108-x

Weitere Artikel der Ausgabe 2/2017

International Journal of Hematology 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.